These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 36962104)
21. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353 [TBL] [Abstract][Full Text] [Related]
22. Challenges and lessons learned during the planning and early implementation of the RTS,S/AS01 Grant J; Gyan T; Agbokey F; Webster J; Greenwood B; Asante KP Malar J; 2022 May; 21(1):147. PubMed ID: 35550113 [TBL] [Abstract][Full Text] [Related]
23. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Day CL; Tameris M; Mansoor N; van Rooyen M; de Kock M; Geldenhuys H; Erasmus M; Makhethe L; Hughes EJ; Gelderbloem S; Bollaerts A; Bourguignon P; Cohen J; Demoitié MA; Mettens P; Moris P; Sadoff JC; Hawkridge A; Hussey GD; Mahomed H; Ofori-Anyinam O; Hanekom WA Am J Respir Crit Care Med; 2013 Aug; 188(4):492-502. PubMed ID: 23306546 [TBL] [Abstract][Full Text] [Related]
24. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives. Semitala FC; Musinguzi A; Ssemata J; Welishe F; Nabunje J; Kadota JL; Berger CA; Katamba A; Kiwanuka N; Kamya MR; Dowdy D; Cattamanchi A; Katahoire AR Implement Sci Commun; 2021 Jun; 2(1):71. PubMed ID: 34193311 [TBL] [Abstract][Full Text] [Related]
25. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG; EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714 [TBL] [Abstract][Full Text] [Related]
26. Vaccination Strategies Against Mycobacterium tuberculosis: BCG and Beyond. Ferluga J; Yasmin H; Bhakta S; Kishore U Adv Exp Med Biol; 2021; 1313():217-240. PubMed ID: 34661897 [TBL] [Abstract][Full Text] [Related]
28. Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis. Weerasuriya CK; Harris RC; Quaife M; McQuaid CF; White RG; Gomez GB Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33799544 [TBL] [Abstract][Full Text] [Related]
29. Improving active case finding for tuberculosis in South Africa: informing innovative implementation approaches in the context of the Kharitode trial through formative research. Kerrigan D; West N; Tudor C; Hanrahan CF; Lebina L; Msandiwa R; Mmolawa L; Martinson N; Dowdy D Health Res Policy Syst; 2017 May; 15(1):42. PubMed ID: 28558737 [TBL] [Abstract][Full Text] [Related]
30. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O; Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213 [TBL] [Abstract][Full Text] [Related]
31. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
33. Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. Shrestha S; Chihota V; White RG; Grant AD; Churchyard GJ; Dowdy DW Am J Epidemiol; 2017 Dec; 186(12):1362-1369. PubMed ID: 29253139 [TBL] [Abstract][Full Text] [Related]
34. Vaccine strategies for the Sharan R; Kaushal D NPJ Vaccines; 2020; 5():95. PubMed ID: 33083030 [TBL] [Abstract][Full Text] [Related]
36. Key issues in the clinical development and implementation of TB vaccines in South Africa. Rustomjee R; Mcleod R; Hanekom W; Steel G; Mahomed H; Hawkridge A; Welte A; Sinanovic E; Loots G; Grobler A; Mvusi L; Gray G; Hesseling A; Ginsberg A; Lienhardt C; Shea J; Tong X; Lockhart S; Churchyard GJ Tuberculosis (Edinb); 2012 Sep; 92(5):359-64. PubMed ID: 22698868 [TBL] [Abstract][Full Text] [Related]
37. Natural and trained innate immunity against Mycobacterium tuberculosis. Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788 [TBL] [Abstract][Full Text] [Related]
38. Prospects for a vaccine to prevent HIV-related tuberculosis. Nemes E; Scriba TJ; Hatherill M Curr Opin HIV AIDS; 2018 Nov; 13(6):522-527. PubMed ID: 30080682 [TBL] [Abstract][Full Text] [Related]
39. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. Montoya J; Solon JA; Cunanan SR; Acosta L; Bollaerts A; Moris P; Janssens M; Jongert E; Demoitié MA; Mettens P; Gatchalian S; Vinals C; Cohen J; Ofori-Anyinam O J Clin Immunol; 2013 Nov; 33(8):1360-75. PubMed ID: 24142232 [TBL] [Abstract][Full Text] [Related]